ArticleBMC infectious diseases2025
Seroprevalence of CMV infection in patients with active ulcerative colitis and underlying factors of pathogenicity.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First Reported Case of Upadacitinib-Associated Cytomegalovirus Viremia and Suspected Pneumonitis in Ulcerative Colitis.ACG case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) infection has garnered increasing attention in the context of active ulcerative colitis (UC), a chronic IBD, characterized by periods of remission and relapse. Exploring the interplay between CMV and UC highlights the need for heightened awareness of viral infections in gastrointestinal disorders, to improve patient management and therapeutic strategies. MATERIALS AND
methodsIn this cross-sectional study, serum samples from 82 patients with Active UC were assessed for CMV serological markers (IgG and IgM antibodies) using the chemiluminescent immunoassay (CLIA) method. Following this, polymerase chain reaction (PCR) was employed to detect CMV DNA in plasma samples using specific primers. The clinical findings along with demographical collected data were analyzed using SPSS version 16 software.
resultsAmong 82 patients with active UC, 12.2% were diagnosed with active CMV infection, and 48% had a history of previous CMV infection (IgG + and IgM-). No significant differences in clinical symptoms or demographic variables among the three patient groups were observed (P > 0.05). However, there was a significant difference in weight loss between patients with active CMV infection and those with IgG + and IgM- (P = 0.040). Additionally, patients with active CMV had significantly higher corticosteroid consumption compared to the other two groups (P = 0.020).
conclusionsThe prevalence of CMV in patients with active UC highlighted the necessity of accurately diagnosing the presence of latent or active CMV infection before initiating treatment. Furthermore, the role of corticosteroid uses in CMV reactivation and the severity of colitis should not be underestimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.